Russian pharmaceutical company PROMOMED and the Cuban state biotechnology and pharmaceutical organization BioCubaFarma have signed a memorandum of understanding. The partnership is aimed at the development, clinical research, and commercialization of polyvalent therapeutic vaccines for the treatment of a wide range of oncological diseases.
Agreement Details
The signing ceremony took place in St. Petersburg during the 23rd session of the Intergovernmental Russian-Cuban Commission on Trade, Economic, Scientific, and Technical Cooperation. The memorandum was signed in the presence of Dmitry Chernyshenko, Deputy Prime Minister of the Russian Federation, and Oscar Pérez-Oliva Fraga, Deputy Prime Minister of Cuba.
The document was signed by Kira Zaslavskaya, Director for New Products at PROMOMED, and Alejandro Padrón, Director of the BioCubaFarma Representative Office in Russia. The agreement defines the principles for organizing joint activities for drug development, pre-clinical and clinical trials, as well as its subsequent registration in global markets.
Scientific Basis and Mechanism of Action
Following an assessment of project prospects, PROMOMED and the Center of Molecular Immunology (CIM) of Cuba, part of the BioCubaFarma structure, agreed to create a vaccine that stimulates the patient’s own immunity to fight malignant neoplasms. The drug’s multi-target approach is designed to address the problem of tumor resistance to existing therapies.
“Solid tumors demonstrate pronounced resistance to standard therapies and a high level of adaptability. Multi-target vaccines are aimed at several antigens at once. Through this comprehensive impact, it is possible to achieve high treatment efficacy and reduce the risk of relapses. This technology lays the foundation for forming new therapy standards focused on long-term remission.”
— Kira Zaslavskaya, Director for New Products at PROMOMED
